 Glioblastoma GBM, the most common and most malignant primary brain tumor, represents a major medical challenge considering its extremely poor prognosis Wen 2008. Current standard of care includes maximal surgical resection, followed by concomitant radio-chemotherapy temozolomide - TMZ RT-CT followed by 6 months of maintenance TMZ, with a median overall survival mOS of 14.6 vs. 12.1 months with RT alone Stupp 2005. Non operable GBM, represents around 30 of cases of GBM, with a poorer prognosis, a median PFS of 3-4 months and a median OS between 6-9 months Chinot 2007, Stupp 2009, with concomitant RT-CT treatment. Therefore, innovative treatment strategies are urgently needed and new treatment combinations evaluated in phase I studies are highly encouraged Wen 2011. 